<div id="readability-page-1"><p>First Trust Advisors LP lowered its stake in  Boston Scientific Corporation (NYSE:BSX - Free Report) by 30.5% during the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor  owned 429,637 shares of the medical equipment provider's stock after selling 188,265 shares during the quarter. First Trust Advisors LP's holdings in Boston Scientific were worth $46,147,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Boston Scientific</strong> alerts:</span></p></div><ul><li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li></ul><p>Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of  Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after buying an additional 2,545,381 shares in the last quarter.  Geode Capital Management LLC raised its holdings in shares of  Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider's stock worth $3,466,320,000 after acquiring an additional 622,602 shares in the last quarter.  Norges Bank purchased a new stake in shares of  Boston Scientific during the 2nd quarter worth approximately $2,089,937,000.  Invesco Ltd. boosted its position in shares of  Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider's stock valued at $1,810,022,000 after acquiring an additional 226,578 shares during the last quarter.  Finally, Amundi grew its holdings in shares of  Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after purchasing an additional 311,034 shares in the last quarter. Hedge funds and other institutional investors own  89.07% of the company's stock. </p><h2>Insider Activity</h2><p>In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company's stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 143,095 shares of company stock valued at $14,228,950. Corporate insiders own  0.50% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><ul><li>3 Healthcare Stocks Using AI to Drive Growth</li></ul><p>BSX has been the subject of several research reports. Canaccord Genuity Group  reiterated a &#34;buy&#34; rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Thursday, October 23rd. Leerink Partners increased their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday, October 1st. Evercore ISI  reiterated an &#34;outperform&#34; rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Needham &amp; Company LLC  restated a &#34;buy&#34; rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Friday, October 17th. Finally, Wall Street Zen raised Boston Scientific from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, October 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued  a Buy rating and two have issued  a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of &#34;Buy&#34; and a consensus target price of $123.77.</p><p><b>Read Our Latest Report on BSX</b></p><h2>Boston Scientific Stock Down 4.0%</h2><ul><li>3 Biotech Catalysts Present Major Opportunity</li></ul><p>NYSE:BSX opened at $93.66 on Tuesday. The company has a market cap of $138.84 billion, a price-to-earnings ratio of 50.08, a price-to-earnings-growth ratio of 1.96 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $99.20 and a 200-day simple moving average of $101.95. </p><p>Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the firm posted $0.63 EPS. The firm's revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS.  Analysts anticipate that  Boston Scientific Corporation will post 2.85 EPS for the current year. </p><h2>Boston Scientific Company Profile</h2> (Free Report)<p>Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Boston Scientific</li><li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>3 Natural Gas Stocks That Offer Great Dividend Yields</li><li>3 Stocks Most Likely to Split in 2026</li><li>What is diluted earnings per share (Diluted EPS)?</li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2><p>Before you consider Boston Scientific, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>First Trust Advisors LP reduced its stake in Boston Scientific Corporation by 30.5% in Q2, selling 188,265 shares. Other institutional investors like Vanguard and Geode Capital increased their holdings. Insider sales included Director Ellen M. Zane and EVP Joseph Michael Fitzgerald. Analysts maintain a 'Buy' rating with a consensus target price of $123.77. Boston Scientific's stock opened at $93.66, with a market cap of $138.84 billion.</p>

First Trust Advisors LP Cuts Stock Holdings in Boston Scientific Corporation $BSX